BIO Comments Re: Comments on Sharing Clinical Trial Data: A Proposal From the International Committee of Medical Journal Editors

Dear Dr. Taichman:


BIO Comments on FDA Natural Food Labeling

The Biotechnology Innovation Organization (BIO) is pleased to submit these comments to FDA in response to FDA’s request for information on the use of the term “natural” on food labeling (docket no. FDA-2014-N-1207). BIO is the world's largest biotechnology trade association, representing companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than thirty other nations. BIO members are involved in the research and development of healthcare, agricultural, industrial and environmental biotechnology products.

BIO Submits Comments Re: Medicare Program; Part B Drug Payment Model [CMS-1670-P]

The Biotechnology Innovation Organization appreciates this opportunity to submit comments on the Centers for Medicare and Medicaid Services’ proposed rule entitled Medicare Program; Part B Drug Payment Model...

Follow-Up on BIO’s Comments in Response to the ICER Value Framework

BIO’s comments to the USDA on the biomass crop assistance program enacted by the 2008 Farm Bill

Comments are regarding conservation and stewardship requirements, matching payments, establishment costs and annual payments, disclosure of competitively sensitive information, invasiveness determination and review, consistency with existing FSA programs, corporations and publicly traded company participation, eligible materials, and algae.

BIO letter in support of H.R. 5418

To establish a pilot program for educating district court judges on patent related issues.

Cures Acceleration Network: Legislative Text


Small Business Early Stage Investment Program: Legislative Text

The Small Business Early Stage Investment Program would provide matching funds for investment companies who invest in small, high tech companies, including biotech firm.

Diran Makinde, Network Director, NEPAD Biosciences, West Africa Biosciences Network (WABNet), Senegal

Government's role in developing solutions for diseases that disproportionately affect developing countries

Mark Rohrbaugh, Director, Office of Technology Transfer, National Institutes of Health (NIH)

Mark Rohrbaugh, Director, Office of Technology Transfer, National Institutes of Health (NIH), US Department of Health & Human Services, USA